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Buruli ulcer (BU) disease, caused by
Mycobacterium ulcerans, is characterized by
severe necrotizing ulcers. The disease, which is
found worldwide but primarily in tropical
climates (1,2), occurs predominantly in children
ages 5 to 14 (3) and is associated with severe
illness and permanent disabilities in >26% of
patients (1,3). Over the past decade, the incidence
of BU disease has dramatically increased in
several West African countries, notably Ghana,
Côte d’Ivoire, Benin, and Togo (1,2). In some
West African communities, BU has replaced
tuberculosis (TB) and leprosy as the most
prevalent mycobacterial disease, affecting up to
22% of the population (4). However, the true
global impact of the disease is unknown because
reliable tools for its rapid diagnosis and
surveillance are lacking. In addition, neither the
mode of transmission nor the environmental
reservoir for M. ulcerans is known, although
observational studies suggest that M. ulcerans
infection is transmitted through the skin after
contact with contaminated water, vegetation (5),
or insects (6).
Current treatment for cutaneous disease is
primarily surgical. Ulcerative lesions require
wide debridement and skin grafting in special-
ized health-care facilities, long hospital stays (7),
and increased cost to the health-care system and
the community (7). Antibiotics are ineffective
once ulcers are present, possibly because
M. ulcerans is absent from lesions or subcutaneous
tissues have already been destroyed, preventing
penetration of antimycobacterial drugs (3).
Antimicrobial therapy has not been studied in
preulcerative lesions because apparently pa-
tients rarely visit primary health-care providers
with painless nodular lesions and diagnostic tests
are not available to clearly identify M. ulcerans
infection before it progresses to clinical disease.
Early identification and surgical excision of these
preulcerative nodular lesions can be curative and
does not require inpatient care (8). We
investigated the serologic response to the
M. ulcerans culture filtrate (MUCF) of BU
patients at different stages of disease to determine
whether serodiagnosis is feasible as a tool for
early diagnosis and intervention of BU disease.
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Buruli ulcer (BU) is an emerging necrotic skin disease caused by Mycobacterium
ulcerans. To assess the potential for a serodiagnostic test, we measured the humoral
immune response of BU patients to M. ulcerans antigens and compared this response
with delayed-type hypersensitivity responses to both Burulin and PPD. The delayed-type
hypersensitivity response generally supported the diagnosis of BU, with overall reactivity
to Burulin in 28 (71.8%) of 39 patients tested, compared with 3 (14%) of 21 healthy
controls. However, this positive skin test response was observed primarily in patients with
healed or active disease, and rarely in patients with early disease (p=0.009). When tested
for a serologic response to M. ulcerans culture filtrate, 43 (70.5%) of 61 BU patients had
antibodies to these antigens, compared with 10 (37.0%) of 27 controls and 4 (30.8%) of
13 tuberculosis patients. There was no correlation between disease stage and the onset
of this serum antibody response. Our findings suggest that serologic testing may be useful
in the diagnosis and surveillance of BU.159 Vol. 6, No. 2, March–April 2000 Emerging Infectious Diseases
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Table 1. Burulin skin test responses of Buruli ulcer patients
and healthy controls from the same villages
Clinical   Burulin Dual   PPD Dual
presentation  (+) only   (+) (+) only   (-)
Total  BU  patients   17   11    6    5
 (n=39) (%) (43.6) (28.2) (15.4) (12.8)
Healed     9     6    1    0
 (n = 16) (%) (56.3) (37.5) (6.2) (0.0)
Ulcerative     7     4    4    2
 (n = 17) (%) (41.2) (23.5) (23.5) (11.8)
Early  ulcerative     1     1    1    3
 (n = 6) (%) (16.7) (16.7) (16.7) (50)
No  scar  or  ulcer     3     0    1  17
 (n = 21) (%) (14.3) (0.0) (4.8) (81)
Each column provides the number (n) and percentage (%) of
persons meeting the criteria for specific skin-test positivity.
Dual (+) persons, being both PPD and Burulin (+), are not
exclusive for either Burulin or PPD positivity and thus are
not included in either of these two columns.
Persons were scored Burulin-only skin-test positive if the
diameter of induration at the site of Burulin injection was  10
mm at 48 or 72 hours and the diameter of induration at the
site of PPD injection was at least 3 mm smaller than in the
Burulin response. Persons were scored as only PPD positive if
the diameter of induration at the site of PPD injection was  10
mm at 48 or 72 hours and the diameter of induration at the
site of Burulin injection was at least 3 mm smaller than that
in the PPD response. Persons were scored as both Burulin
and PPD skin-test positive if the diameters of induration of
both the Burulin and PPD injection sites were  10 mm at 48 or
72 hours and the differences in the diameters of the zone of
induration between the two was <3 mm. Persons were scored
as skin test negative for both if the induration at both
injection sites was <10 mm at 48 or 72 hours.
Table 2. Serologic and skin test responses of Buruli ulcer
patients and healthy controls from the same villages
Clinical      Total      AB to
presentation Burulin (+)a MUCFb (+)c
Total  BU  patients   28   26
 (n = 39) (%) (71.8) (66.7)
Healed   15   11
 (n = 16)  (%) (93.8) (68.8)
Ulcerative   11   11
 (n = 17) (%) (64.7) (64.7)
Early  ulcerative     2     4
 (n = 6) (%) (33.4) (66.7)
No  scar  or  ulcer     3     7
 (n = 21) (%) (14.3) (33.3)
aTotal Burulin (+) numbers and (%) are derived from columns
one and two of Table 1 added together without regard to PPD
status, and thus represent the highest possible number
(percentage) of Burulin (+) BU patients.
bMUCF = Mycobacterium ulcerans culture filtrate
cDenotes all BU patients and controls with any antibodies
detected by Western blot analysis against MUCF.
The Study
BU patients were identified through a case-
control study conducted in 1991 in the Daloa
region of Côte d’Ivoire (3). Patients with early
ulcerative BU were identified by small, painless,
or minimally painful nodules or edema, or
ulcerative lesions for <2 weeks. Patients with
ulcerative BU were identified by lesions that
were chronic (>2 weeks duration), were painless
or minimally painful, or had undermined edges.
Patients with healed BU were identified by stellate
scars with retraction in areas of prior ulceration.
Descriptive and clinical data were obtained from
all BU patients and controls (3). Blood specimens
were collected from 82 BU patients and 164
healthy controls in the Daloa region.
Because TB is endemic in many of the areas
where BU occurs, 13 TB patients from the United
States were used as controls for cross-reactivity to
MUCF. Use of sera from these patients ensured
the lowest probability for exposure to M. ulcerans,
so that only cross-reactivity to antigens common
to both M. tuberculosis and M. ulcerans would be
measured. TB patients were identified through
an ongoing study in Atlanta by clinical
presentation, a positive PPD response, and
isolation of M. tuberculosis from sputum. All
specimens tested negative for HIV and were
strongly reactive to many of the culture filtrate
antigens from M. tuberculosis (data not shown).
Informed consent was obtained for all partici-
pants, and protocols were approved by the
Institutional Review Boards of the Centers for
Disease Control and Prevention and the Ministry
of Health of Côte d’Ivoire for the BU study and the
Institutional Review Board at Emory University
for the TB study.
Skin Testing
During sera collection, Burulin (9) and PPD
(purified protein derivative of M. tuberculosis,
Connaught Laboratories, U.K.) were adminis-
tered intradermally into the flexor surface of the
forearms of 39 BU patients and 21 controls, and
the diameter of induration was recorded at 48 and
72 hours. The criterion for using Burulin and PPD
dual testing to confirm clinical cases of BU has
been reported (3,9), and the cumulative delayed-
type hypersensitivity (DTH) findings for this
study have been described (Table 1) (3). Sera
were also tested for reactivity to MUCF antigen
by Western blot (Table 2).160 Emerging Infectious Diseases Vol. 6, No. 2, March–April 2000
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Preparation of MUCF Antigen for Serologic
Analysis
M. ulcerans strain S-WT (from the Centers for
Disease Control and Prevention culture collec-
tion; Atlanta) was recovered from a 1-ml
lyophilisate in 10% glycerol by incubation in 5 ml
Middlebrook 7H9 with OADC supplement
(Remel, Lenexa, KS) at 32.5°C for 7 days. This
5-ml inoculum was passaged into 25 ml
Middlebrook 7H9 broth supplemented with
tryptose and glucose (7H9TG; 0.1% wt:vol and 2%
wt:vol, respectively) and incubated at 32.5°C for
10 days, followed by passage into 100 ml of
7H9TG and growth at 32.5°C for 10 days.
Cultivation in this protein- and serum-free media
allowed isolation and analysis of specific secreted
mycobacterial proteins. The 100-ml culture was
passaged into 1L of 7H9TG, incubated at 32.5°C
in 850-cm2 roller bottles, and rotated at 90
rotations per hour. Bacilli were harvested during
mid-log phase growth by centrifugation. The 1L
of MUCF, containing mycobacterial proteins of
interest, was concentrated at 4°C under N2 by
using a stirred-cell apparatus (Amicon Inc.,
Beverly, MA) with a 10-kDa molecular weight
membrane. MUCF was exchanged into 0.1 M
NH4HCO3 by dialysis, lyophilized, and purified
by separation of residual small molecular weight
contaminants from antigens of interest by size
exclusion chromatography. MUCF was loaded
onto a fast-performance liquid chromatography
system (FPLC) (Pharmacia, Piscataway, NJ)
equipped with a G-25 superfine Sephadex
desalting column (Pharmacia, Piscataway, NJ),
UV monitor, and conductivity monitor for
separation and detection of proteins and salts,
respectively. MUCF was eluted with an isocratic
gradient of 0.1 M NH4HCO3. MUCF protein was
quantitated by bicinchoninic acid assay (Pierce
Chemical Co., Rockford, IL) and lyophilized until
needed. Approximately 5 mg of MUCF protein
was obtained per liter of culture.
Aliquots of 8  g of MUCF protein were
resolved by discontinuous sodium dodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE)
(10) by using 10% to 20% gradient 10-well gels
(Novex, San Diego, CA). MUCF proteins were
visualized by staining with silver (11), and this
profile was reexamined throughout these
experiments to ensure that the MUCF proteins
did not degrade upon storage; no antigen
variability was seen during our studies. 7H9TG
media alone processed in the same way contained
no proteins by silver stain analysis after SDS-
PAGE and bicinchoninic acid assay.
Amino Acid Sequence Analyses
The N-terminal amino acid sequences of
MUCF proteins were determined and compared
with known mycobacterial sequences. One
hundred micrograms of MUCF protein was
resolved by two-dimensional gel electrophoresis
(2D-GE) by the method of O’Farrell (12) with the
modifications of Sonnenberg and Belisle for
resolution of mycobacterial proteins (13). 2D-GE
resolved proteins were transferred to 0.1 mm
polyvinyl difluoride (PVDF) membrane (14) and
visualized by staining with 0.5% Coomassie blue
R250 in 40% methanol/10% acetic acid for 2
minutes. The N-terminal amino acid sequence
was obtained by loading membranes containing
the excised spot of interest onto a Procise-cLC
automated Edman sequencer (Applied
Biosystems, Foster City, CA) and reading the
generated chromatographs against amino acid
standards.
Statistical Analyses
Statistical analyses were done by the Mantel-
Haenszel chi-square method. Statistical signifi-
cance for the chi-square p values and Fisher’s
exact p values was evaluated at  α  = 0.05. Fisher’s
exact p value was used when the expected cell
count was <5. Odds ratios (OR) were determined
by calculating the ratio of the odds of exposure
among cases to that among controls. The test for
specificity was determined by dividing the true
negatives (n = 24; disease-negative and 70 kDa-
negative) by the total number of controls (n = 27).
All analyses were done on BU patients and
healthy controls from the Daloa region of Côte
d’Ivoire, where the disease is endemic, unless
otherwise specified. All data were analyzed by
using Exact 2.0b software (D. Martin and H.
Austin, Atlanta, GA).
Results
Seventeen (43.6%) of the 39 skin-tested BU
patients had induration of > 10 mm within 72
hours of Burulin administration, with PPD
induration at least 3 mm smaller than that with
Burulin (Table 1). Only 3 (14.3%) of the 21 skin-
tested healthy controls from the area had a
similar DTH pattern (Table 1). In addition, 11
(28.2%) of the 39 BU patients had an equally
strong response to Burulin and PPD, which161 Vol. 6, No. 2, March–April 2000 Emerging Infectious Diseases
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Figure. Western blot reactivity to and Silver stain
analysis of Mycobacterium ulcerans culture filtrates
(MUCF). A) Representative antibody responses to
MUCF. M; molecular weight markers with annota-
tions corresponding to molecular weight on the left;
lanes 1-6, representative BU patient sera with
reactivity to MUCF; lanes 7-10, representative
antibody reactivity in healthy persons from the
disease-endemic area; lanes 11-12, serologic reactivi-
ties to MUCF of two representative tuberculosis (TB)
patients. TB patient sera that were serologically
reactive to MUCF were included as a control for cross-
reactivity. Regions of antibody reactivity correspond-
ing to M. ulcerans antigens of 70, 38/36, and 5 kDa are
noted (arrows). B) Silver-stained SDS-PAGE gel of
MUCF. The identification of putative proteins
corresponding to the serologically reactive 70, 38/36,
and 5 kDa MUCF antigens are noted (stars). For
Western blot analyses, aliquots (50 ￿g protein) of
MUCF were resolved by discontinuous SDS-PAGE
(10) with preparative 10% to 20% gradient 1-well gels
(Novex, San Diego, CA) and then transferred to
nitrocellulose (14). Nitrocellulose sheets were cut into
2-mm strips and stored in 5% skim milk in Tris-
buffered saline, pH 7.6, until used. Antibody to MUCF
was detected by probing nitrocellulose strips with
sera at a 1:50 (vol:vol dilution). Bound serum
antibodies were detected with alkaline phosphatase-
conjugated anti-human antibody (Sigma Chemical
Co., St. Louis, MO), and the substrate 4-Bromo-3-
Chloro-2-Indoyl-1-Phosphate/Nitro blue tetrazoleum
(Sigma Chemical Co., St. Louis, MO). All sera were
tested in duplicate for confirmation of the antibody
responses.
suggests that Burulin skin testing may not be
reliable in regions where BU and TB are endemic
and BCG vaccination is widely used (Table 1).
Dual-positive responses included, 28 (71.8%) of
the 39 BU patients were Burulin positive.
However, when this total Burulin-positive
population was delineated by disease stage,
positive responses were observed in most of the
patients with healed (93.8%) and ulcerative
disease (64.7%), but in few (33.4%) patients with
early ulcerative disease (Table 2). When healed
and active Burulin responses were compared
with the DTH response seen in early ulcerative
BU patients, a significant difference between the
disease stages was found (Fisher’s exact p = 0.009).
These skin-tested BU patient and control
populations from the Daloa region were then
tested for reactivity of their sera to MUCF by
Western blot, and Burulin induration was
compared with serum antibody response (Table
2). Twenty-six (66.7%) of the 39 skin-tested BU
patients had an antibody response to the MUCF,
versus 7 (33.3%) of the 21 skin-tested controls
(chi-square p = 0.014). BU patient populations
had approximately the same positive antibody
responses to the MUCF, regardless of disease
stage. Specifically, 68.8% of the healed patients
were antibody positive, with active ulcerative
disease at 64.7% and early disease at 66.7%
(Table 2). When the antibody responses of healed
and active patients were compared with those
seen in early BU patients, the serologic response
did not differ significantly by disease stage
(Fisher’s exact p = 0.999). Therefore, serologic
testing may be useful in the early diagnosis and
surveillance of BU.
The antibody response to the MUCF was then
determined for all 61 clinically diagnosed BU
patients and 27 healthy controls, and antibody
reactivity to individual antigens was recorded.
Three  M. ulcerans antigens of 70, 38/36, and 5
kDa were commonly recognized by BU patient
sera antibodies (Figure). The 36-kDa antigen was
found to be a degradation product of the 38-kDa
antigen (unpub. results). Forty-three (70.5%) of
61 BU patient sera had antibodies to at least 1 of
3 antigens, compared with 10 (37.0%) of 27 sera
from healthy controls from the area and 4 (30.8%)
of 13 sera from TB patients (Table 3). The
antibody response to the 70-kDa M. ulcerans
antigen was associated with BU disease (OR =
12.33; chi-square p = 0.00002), and the response
to this protein was consistent throughout early to
late disease stage (OR = 12.4; chi-square
p = 0.0000001; Table 3). Results were similar for
the 38/36-kDa antigen (OR = 5.94; chi-square
p = 0.0016), regardless of disease stage
(OR = 3.00; chi-square p = 0.0026). The162 Emerging Infectious Diseases Vol. 6, No. 2, March–April 2000
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Table 3. Antibody responses to specific Mycobacterium ulcerans culture filtrate proteins in all Buruli ulcer patients and
controls
Clinical  presentation   5 kDa 36/38  kDa  70 kDa All  three    Anya
Total BU patients (n= 61) (%) 14 (22.9) 31 (50.8) 37 (60.7) 8 (13.1) 43 (70.5)
Healed (n = 29) (%)   8 (27.6) 15 (51.7) 17 (58.6) 7 (24.1) 20 (69.0)
Ulcerative (n = 22) (%)   6 (27.3) 10 (45.5) 14 (63.6) 2 (9.1) 16 (72.7)
Early  ulcerative  (n=10)  (%)   0 (0.0)   6 (60.0)   6 (60.0) 0 (0.0)   7 (70.0)
No scar or ulcer (n= 27) (%)   7 (25.9)   4 (14.8)   3 (11.1) 1 (3.7) 10  (37.0)
U.S. TB patients (n= 13) (%)   3 (23.1)   3 (23.1)   0 (0.0) 0 (0.0)   4 (30.8)
aDenotes total number (percentage) of persons within the population with an antibody response to any one, or a mixture of, the
three specified MUCF proteins. MUCF = Mycobacterium ulcerans culture filtrate
N-terminal amino acid sequence of the 38 kDa
protein was DPAPAPAPRD, and had mycobacte-
rial sequences that precede glycosylation sites (15).
The serologic response to the 5-kDa antigen,
although common in the seroreactive specimens
tested, did not differ significantly between BU
patients and healthy controls from disease-
endemic areas or TB patients (chi-square p =
0.764 and Fisher’s exact p = 0.999, respectively);
nor were antibodies to this antigen observed in
BU patients at the early ulcerative stage (Table
3). A cross-reactive serologic response to MUCF
was observed in some TB patients who had not
been exposed to M. ulcerans and in some healthy
controls from disease-endemic areas (Figure;
representative sample and Table 3). These
positive responses may be due to exposure to
other mycobacterial pathogens with similar
antigens as M. ulcerans or BU disease
undetectable by clinical diagnosis, respectively.
Conclusions
Diagnosis of BU currently relies on the
clinical presentation of the ulcerative disease
stage, by which time the infection has already
caused damage, therapeutic options are limited,
and outcome is associated with severe disease
(3,7,8). Preulcerative nodules and edemous
lesions, when identified, frequently contain
numerous extracellular mycobacteria (1,2). Thus,
diagnosis of BU disease at this early stage may
lead to more effective treatment. Indeed,
diagnosis of preulcerative BU disease is
associated with a better therapeutic outcome and
reduced illness (8), and accurate surveillance at
the preulcerative stage would enable assessment
of the prevalence and global impact of BU
disease. Surveillance may also identify risk
factors as well as prevention strategies for BU.
Consistent with previous reports (3,9), DTH
to Burulin, a crude preparation of M. ulcerans
lysate (9), was observed in many (71.8%) of the
clinically diagnosed BU patients. This overall
response was similar to the well-defined cell-
mediated DTH responses reported for other
mycobacterial infections (16-18), including
M. tuberculosis (19,20). In contrast, in BU
patients,  the Burulin response was associated
with ulcerative and healed disease, but not with
early ulcerative disease. Thus, unlike other DTH-
based monitoring programs that indicate myco-
bacterial infection before and during disease in
immunocompetent persons, Burulin testing may
be more useful for confirming ulcerative disease
or monitoring past disease with  M. ulcerans in
conjunction with PPD results.
The marked shared reactivity to PPD and
Burulin antigens by BU patients, as measured by
similar induration upon intradermal injection,
was expected to some degree, considering the
commonality of antigenic lipids on the mycobacte-
rial surface, genetic relatedness of mycobacterial
pathogens, opportunity of exposure to both
mycobacterial pathogens and environmental
mycobacteria, and rate of BCG vaccination in the
region. When Burulin-positive results were
analyzed in conjunction with either the presence
of a BCG vaccination scar or recollection of BCG
vaccination, 12 of 14 BCG-vaccinated BU
patients were Burulin positive, and 6 of these 12
patients were also PPD positive. Additionally, all
the Burulin- and PPD-positive controls either
recalled BCG vaccination or had a BCG scar (data
not shown).
We found that a specific response to the
MUCF was observed in BU patient sera, but
unlike the Burulin DTH response, the antibody
response did not correlate with disease stage163 Vol. 6, No. 2, March–April 2000 Emerging Infectious Diseases
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(Table 2). The antibody reactivity in the sera from
some of the controls from disease-endemic areas
may reflect preclinical infection with M. ulcerans
or exposure to other mycobacteria and cross-
reactivity to antigens common to mycobacterial
species. Interestingly, 10 (55.6%) of the 18
antibody-negative BU patients, versus 15 (33%)
of the 43 antibody-positive BU patients, recalled
or had a BCG vaccination scar, which suggests
that BCG vaccination did not contribute to the
antibody response of BU patients to MUCF (data
not shown).
Thirty percent of the TB patient sera were
reactive to MUCF, with reactivity principally
towards lower molecular weight proteins and not
the 70- or 38/36-kDa proteins (Figure; Table 3).
N-terminal amino acid sequence of one of these
lower molecular weight proteins, a 31 kDa
protein, was found to be FSRPGLPVEY and
demonstrated homology with the mycolyl
transferases found in M. tuberculosis and other
mycobacteria (21). Thus, reactivity of the TB
patient sera based on antibodies generated
against common mycobacterial antigens is the
likely explanation for the few TB patient sera
reactive to MUCF.
Our preliminary results indicate the useful-
ness of the MUCF in detecting BU; specifically,
individual antigens in the MUCF may be used for
the development of a sensitive and specific test
for BU (Table 3). Both the 70- and 38/36-kDa
proteins were indicators of BU disease, and
antibody responses to both of these proteins were
similarly present in BU-reactive patient serum
samples, regardless of disease stage. In addition,
reactivity to the 70-kDa protein was specific for
M. ulcerans infection (88.8%).
The 70- and 38/36-kDa proteins may be
useful for the development of a serologic test for
BU in areas where TB is endemic. Based on these
results, we are isolating and characterizing these
two  M. ulcerans antigens for additional testing.
The N-terminal sequence for the 38/36-kDa
protein has already been determined as part of
the purification process for this protein, and
identification and purification of the 70-kDa
protein are under way. If a serologic test proves to
be diagnostic, early excision of nodules and
antimycobacterial chemotherapy trials of pa-
tients could reduce the public health and
socioeconomic impact of this emerging disease.
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